Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial Carolyn Chiswick, MBChB, Prof Rebecca M Reynolds, PhD, Fiona Denison, MD, Amanda J Drake, PhD, Shareen Forbes, PhD, Prof David E Newby, DSc, Prof Brian R Walker, MD, Prof Siobhan Quenby, MD, Prof Susan Wray, PhD, Prof Andrew Weeks, MD, Hany Lashen, MD, Aryelly Rodriguez, MSc, Prof Gordon Murray, PhD, Sonia Whyte, MSc, Prof Jane E Norman, MD The Lancet Diabetes & Endocrinology Volume 3, Issue 10, Pages 778-786 (October 2015) DOI: 10.1016/S2213-8587(15)00219-3 Copyright © 2015 Chiswick et al. Open Access article distributed under the terms of CC BY Terms and Conditions
Figure Trial profile *Change in eligibility from screening of notes to recruitment visit (unable to arrange recruitment visit before 16 weeks [n=26]), recruitment stopped before screening appointment (n=14), miscarriage (n=2), moved out of area (n=1), unable to provide informed consent because of difficulties with spoken English (n=5), own doctor or midwife advised against participation (n=4), duplicate note screening number issued in error (n=4). †3 months after birth. The Lancet Diabetes & Endocrinology 2015 3, 778-786DOI: (10.1016/S2213-8587(15)00219-3) Copyright © 2015 Chiswick et al. Open Access article distributed under the terms of CC BY Terms and Conditions